Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Biopharmaceutical company Sunesis Pharmaceuticals has received positive results from a phase I clinical trial of its investigational compound SNS-595, indicating that it has potential cancer fighting properties.
Subscribe to our email newsletter
The phase I clinical trial recruited 41 patients with advanced solid tumors and was designed to examine the safety, tolerability, and pharmacokinetics of escalating doses of SNS-595. Results from the study demonstrate evidence of sustained disease control using SNS-595 among a variety of tumor types, with one confirmed partial response as well as 12 patients achieving stable disease for more than twelve weeks.
The phase I clinical trial was an open-label multi-center study in which patients received increasing doses of SNS-595 by intravenous injection every three weeks for up to six cycles.
In the study, SNS-595 was well tolerated. The dose-limiting effect was a reversible decrease in the white blood cell count, while non-hematologic side effects observed were mild and easily managed.
Pharmacokinetics were highly reproducible and consistent across patients. In addition, a maximum tolerated dose of 48mg/m squared was established through this study.
Dr Daniel Adelman, senior vice president of R&D at Sunesis said: “This anti-tumor response, combined with SNS-595’s tolerability, predictable pharmacokinetics and unique mechanism of action provide strong support for this drug’s continued development. We are initiating several phase II clinical trials of SNS-595 in separate tumor settings to determine the optimal therapeutic applications and regulatory strategy for this product.”